August 19, 2026
1 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
mRNA melanoma vaccine-pembrolizumab combo shows survival gains in late-stage trial
A phase 3 trial found that a combination of intismeran autogene plus pembrolizumab improved recurrence-free and distant metastasis-free survival in patients with high-risk melanoma, according to topline data from the manufacturer.The randomized, double-blind INTerpath-001 trial evaluated intismeran autogene (intismeran; Merck, Moderna), an investigational mRNA-based individualized neoantigen
475 words~2 min read
